Immunotherapy for HER-2 positive breast cancer

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: March 16, 2023

Immunotherapy is a developing treatment for advanced breast cancer. has clinical significance the of triple-negative cancers and human epidermal growth factor receptor-2 positive (HER2+) cancers. As proved effective passive immunotherapy, application monoclonal antibodies trastuzumab, pertuzumab T-DM1 (ado-trastuzumab emtansine) significantly improved survival patients with HER2+ Immune checkpoint inhibitors that block programmed death receptor-1 its ligand (PD-1/PD-L1) have also shown benefits cancer in various trials. Adoptive T-cell immunotherapies tumor vaccines are emerging as novel approaches to treating cancer, but require further study. This article reviews recent advances immunotherapy

Language: Английский

---

An Immune‐Enhancing Injectable Hydrogel Loaded with Esketamine and DDP Promotes Painless Immunochemotherapy to Inhibit Breast Cancer Growth

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(29)

Published: Aug. 9, 2024

Abstract Chemotherapy is the cornerstone of triple‐negative breast cancer. The poor effectiveness and severe neuropathic pain caused by it have a significant impact on immune system. Studies confirmed that cells in tumor microenvironment (TME), critical roles regulation prognosis. In this study, revealed painless administration Esketamine, combined with Cisplatin (DDP), can exert an anti‐tumor effect, which further boosted hydrogel delivery It also discovered Esketamine DDP co‐loaded Poloxamer Hydrogel (PDEH) induces local immunity increasing mature Dendritic Cells (mDCs) activated T PDEH group while regulatory (Tregs) known as CD4 + CD25 FoxP3 decreased significantly. Finally, , CD8 spleen exhibited increase, suggesting lasting PDEH. This study proposes serve modulator, enhancing effect poloxamer DDP. Along improving microenvironment, potentially alleviate anxiety depression. With its outstanding bio‐safety profile, offers promising new possibilities for clinical therapy.

Language: Английский

---

Breast cancer immunotherapy: Realities and advances

Cancer Innovation, Journal Year: 2024, Volume and Issue: 3(5)

Published: Sept. 22, 2024

Breast cancer (BC) is the most common malignant tumor and main cause of death in women worldwide. With increased knowledge regarding escape mechanisms advances immunology, many new antitumor strategies such as nonspecific immunotherapies, monoclonal antibodies, anticancer vaccines, oncolytic viruses, among others, make immunotherapy a promising approach for treatment BC. However, these approaches still require meticulous assessment readjustment resistance modest response rates remain important barriers. In this article, we aim to summarize recent data available BC include results ongoing clinical trials approved therapies used monotherapies or combination with conventional treatments.

Language: Английский

---

Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review

Vaccines, Journal Year: 2022, Volume and Issue: 10(8), P. 1249 - 1249

Published: Aug. 3, 2022

Breast cancer is the leading cause of death in women from 20 to 59 years old. The conventional treatment includes surgery, chemotherapy, hormonal therapy, and immunotherapy. This immunotherapy based on administering monoclonal therapeutic antibodies (passive) or vaccines (active) with purposes. Several types could be used as potential treatments for cancer, including whole-cell, DNA, RNA, peptide-based vaccines. Peptides develop are derived tumor-associated antigens tumor-specific antigens, such HER-2, MUC1, ErbB2, CEA, FRα, MAGE A1, A3, A10, NY-ESO-1, among others. Peptide-based provide some advantages, low cost, purity antigen, induction humoral cellular immune response. In this review, we explore different against breast a specific focus description vaccines, their composition, response induction, new targets.

Language: Английский

---

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

Cells, Journal Year: 2022, Volume and Issue: 11(23), P. 3717 - 3717

Published: Nov. 22, 2022

The tumor necrosis factor (TNF) superfamily member TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells via death receptor (DR) activation with little toxicity to normal or tissues. selectivity for activating confers an ideal therapeutic characteristic TRAIL, which has led the development and clinical testing of many DR agonists. However, TRAIL/DR targeting therapies have been widely ineffective trials various malignancies reasons that remain poorly understood. Triple negative breast (TNBC) worst prognosis among cancers. Targeting TRAIL pathway shown notable efficacy a subset TNBC preclinical models but again not appreciable activity trials. In this review, we will discuss signaling components mechanisms governing trial findings discussed focus on TNBC. Challenges potential solutions using agonists clinic are also discussed, including consideration pharmacokinetic pharmacodynamic properties agonists, patient selection by predictive biomarkers, combination therapies. Moreover, recent impact treatment immune response, as well novel strategies address those challenges, discussed.

Language: Английский

---